Healthy Volunteers Clinical Trial
Official title:
Energy Intake Response to Short-Term Alterations of Energy Expenditure in Humans
One reason people gain weight is eating more calories from food than what they need for energy over 24 hours. Metabolism is the amount of energy a person uses over 24 hours. Researchers want to study the relationship between changes in metabolism and how much a person eats. Objectives: To see how much food a person eats when the body's temperature is cooled. To study how changes in metabolism may alter the amount of food a person eats. Eligibility: Healthy people ages 18-55. Design: Participants will stay at NIH for 20 days. During the first 4 days, participants will have: - Medical exam - Electrocardiogram - Blood and urine tests. One blood test includes drinking a sugar solution. - DXA body composition scan - Questions about foods they like, physical activity, and personal behavior - Exercise test on a stationary bicycle Participants will spend 24-hour periods in a metabolic chamber. The chamber will be at normal room temperature or cooler. Some times, participants will eat a diet that matches their daily needs. Other times, they can eat as much as they wish from a vending machine. Participants will have blood and urine collected. Participants will swallow an ingestible wireless sensor and wear a small data recorder device. On the second to last day, participants will stay in the metabolic chamber but only consume water and non-caffeinated sugar-free beverages. Participants will come back for 1-day visits at six months and one year from the first admission. They will have blood and urine tests, and a DXA scan. They will answer questions on physical activity and food habits.
Status | Recruiting |
Enrollment | 160 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility | - INCLUSION CRITERIA: - Premenopausal women and men <55 years of age - Body weight <204 kg (<450 pounds) and >= 36 kg (>= 80 pounds) - Stable weight (+/-5% within past 6 months) as determined by volunteer report - Healthy, as determined by medical history, physical examination, and laboratory tests EXCLUSION CRITERIA: - Age <18 years - Weight greater than or equal to 204 kg (greater than or equal to 450 pounds, maximum weight of the iDXA machine as per manufacturer s manual), or weight <36 kg (<80 pounds, minimum weight allowed based on the NIH guidelines of blood drawing for research purposes) - Use of medications affecting metabolism and appetite in the last three months - Expresses unwillingness to consume all food given during the weight maintaining diet portions of the study (e.g., due to strict dietary restrictions including allergies or vegetarian or kosher diet) - Current use of tobacco products, marijuana, amphetamines, cocaine, or intravenous drug use - Current pregnancy, pregnancy within the past 6 months or lactation - History or clinical manifestation of: - Type 1 and Type 2 diabetes mellitus - History of surgery for the treatment of obesity - Endocrine disorders, such as Cushing s disease, pituitary disorders, and hypo and hyperthyroidism - Pulmonary disorders, including chronic obstructive pulmonary disease - Cardiovascular diseases, including coronary heart disease, heart failure, arrhythmias, and peripheral artery disease - High blood pressure by sitting blood pressure measurement using an appropriate cuff higher than 140/90 mmHg on two or more occasions, or current antihypertensive therapy - Liver disease, including cirrhosis, active hepatitis B or C, and AST or ALT greater than or equal to 2x normal - Gastrointestinal disease including Crohn s disease, ulcerative colitis, celiac disease or other malabsorptive disorders - Abnormal kidney function (eGFR <60 mL/min/1.73m(2)) - Central nervous system disease, including previous history of cerebrovascular accidents, dementia, neurodegenerative disorders or history of severe head trauma - Cancer requiring treatment in the past five years, except for nonmelanoma skin cancers or cancers that have clearly been cured - Infectious disease such as active tuberculosis, HIV (by self report), chronic coccidiomycoses or other chronic infections that might influence EE and weight - Diagnosis of binge eating disorder, anorexia and major psychiatric disorders based upon the DSM-IV including depression, schizophrenia and psychosis, which may impact the ability of the participant to be in the respiratory chamber for 24 hour time periods - Chronic ethanol use (more than 3 drinks/day) |
Country | Name | City | State |
---|---|---|---|
United States | NIDDK, Phoenix | Phoenix | Arizona |
Lead Sponsor | Collaborator |
---|---|
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To investigate whether increases in EE lead to increased ad libitum food intake, as measured using a vending machine paradigm. | metabolic chamber to measure EE; vending machine paradigm to measure food intake | Days 5, 6-9, 12, 13, 16, 19, 20 | |
Primary | To determine whether the effects of increased EE due to cool temperature exposure on energy intake are only concomitant with the increase in EE or persist until the following day. | metabolic chamber to measure EE; vending machine paradigm to measure food intake | Days 5, 6-9, 12, 13, 16, 19, 20 | |
Secondary | To determine if any observed association between EE and energy intake predicts future weight change at 6 months and 1 year. | weight; metabolic chamber to measure EE; vending machine paradigm to measure food intake | Days 1-20, 6 month and 1 year follow-up visits | |
Secondary | To assess if concentrations of appetitive or exercise-induced hormones will correlate with the observed changes in EE and energy intake. | blood and urine collection to determine biomarker concentrations; metabolic chamber to measure EE; vending machine paradigm to measure food intake | Days 5, 6, 9, 12, 13, 16, 19, 20 | |
Secondary | To assess whether the above behavioral testing as measured by previously validated questionnaires and tasks are associated with measured food intake or hormone concentrations. | blood and urine collection to determine biomarker concentrations; metabolic chamber to measure EE; vending machine paradigm to measure food intake | Days 5, 6, 9, 12, 13, 16, 19, 20 | |
Secondary | To assess if behavioral testing addressing dietary restraint, stress related eating behaviors, and executive function or the responses to visual analogue scales assessing hunger modify any observed EE to energy intake association. | questionnaires for food preferences, physical activity, dietary restraint, power of food, emotional overeating, frequency, stress, food security, anhedonia, and cognitive factors; metabolic chamber to measure EE; vending machine paradigm to measure food intake | Days 1-2, 5, 6-9, 12, 13, 16, 19, 20 | |
Secondary | To determine if the 24h EE responses to cool temperature exposure correlate with core body temperature or changes in peripheral skin temperatures, and to determine if these changes are related to body adiposity or associated with food intake. | core body temperature; skin temperature; metabolic chamber to measure EE; vending machine paradigm to measure food intake | Days 5, 6-9, 12, 13, 16, 19, 20 | |
Secondary | To determine if the interventions will alter the 24h respiratory quotient (RQ, an approximation for the ratio of carbohydrate-to-fat oxidation rates), and test whether the induced RQ changes independently contribute to the altered energy intake. | metabolic chamber to measure RQ and EE; vending machine paradigm to measure food intake | Days 5, 9, 12, 16, 19 | |
Secondary | To determine whether 36 hrs of fasting will result in a change in energy intake on the following day, and to determine whether the decrease in 24h EE during fasting will correlate with amount of food consumed the following day. | metabolic chamber to measure EE; vending machine paradigm to measure food intake | Days 5, 6-9, 12, 13, 16, 19, 20 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |